This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The number of industry clinical trials initiated in the UK, per year, fell by 41 percent from 2017 to 2021, according to the latest annual report on clinical research from the Association of the British Pharmaceutical Industry ( ABPI ). million people living with rare diseases in the UK.
The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceuticalcompanies communicate, visit and engage with physicians. His vision is to transform the way businesses operate by helping them increase speed to market while also improving patientcare.
“At the end of the day, I think technological integration will be key and we want to find that sweet spot between the clinician’s time, optimizing patientcare, and ultimately providing the best patientcare,” she said.
Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceuticalcompany – our recent interview provided some interesting insights into the changing landscape of the industry.
Medicaid lowered the cost of drugs reimbursed by state Medicaid agencies by requiring pharmaceuticalcompanies to enter into a rebate agreement with the Secretary of the Department of Health and Human Services (HHS) as a precondition for coverage of their drugs by Medicaid as well as Medicare Part B. billion in 2017.
The platform is being used by leading healthcare organizations to achieve significant ROI, improve health outcomes, attain the highest quality ratings, and reduce cost of care. Strong relationships mean coordinated care, more time on what matters most, information sharing, trust, understanding.
The platform is being used by leading healthcare organizations to achieve significant ROI, improve health outcomes, attain the highest quality ratings, and reduce cost of care. Strong relationships mean coordinated care, more time on what matters most, information sharing, trust, understanding.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content